New York’s Loose Regulations on Medical Cannabis Leave Patients in the Dark
For Kobi Russell, the high from cannabis brought temporary relief from his anxiety, but it ultimately led to a downward spiral of addiction and psychosis. His experience is a stark reminder of the disconnect between New York’s lax regulations on medical cannabis and the scientific evidence on its effectiveness.
A recent study published in Lancet Psychiatry found no significant benefit in using cannabinoids to treat anxiety, PTSD, or psychotic disorders. For depression, the study found no randomized controlled trials at all. The review also highlighted the risks associated with cannabinoids, including side effects such as nausea and dizziness.
Despite these findings, New York has no restricted list of qualifying diagnoses for medical cannabis. Practitioners can certify patients for any condition they deem appropriate, leaving patients and providers with little guidance on the treatment’s effectiveness.
The Office of Cannabis Management in New York has defended the state’s approach, citing the need for individualized treatment plans. However, critics argue that this approach is too permissive and may delay patients from accessing treatments that actually work.
The Lancet study’s authors are calling for stronger regulatory oversight and better training for health workers recommending cannabinoids. They also raised concerns that medical cannabis, prescribed without adequate evidence, may delay patients from accessing evidence-based treatments, such as cognitive behavioral therapy.
Kobi’s story serves as a cautionary tale about the dangers of self-medicating with cannabis for anxiety. Without proper regulation and oversight, patients may be left in the dark about the treatment’s effectiveness and risks.
As New York continues to navigate the complex issue of medical cannabis, it is essential to prioritize evidence-based decision-making and ensure that patients have access to safe and effective treatments for their mental health conditions.
